TWI274751B - Acyloxypyrrolidine derivatives, preparation thereof and application thereof in therapeutics - Google Patents
Acyloxypyrrolidine derivatives, preparation thereof and application thereof in therapeutics Download PDFInfo
- Publication number
- TWI274751B TWI274751B TW092119736A TW92119736A TWI274751B TW I274751 B TWI274751 B TW I274751B TW 092119736 A TW092119736 A TW 092119736A TW 92119736 A TW92119736 A TW 92119736A TW I274751 B TWI274751 B TW I274751B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- formula
- oxy
- dihydro
- methoxyphenyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000003814 drug Substances 0.000 title abstract description 3
- 238000000034 method Methods 0.000 claims abstract description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 88
- -1 2,4-dimethoxyoxyphenyl Chemical group 0.000 claims description 35
- 150000003839 salts Chemical group 0.000 claims description 18
- 208000024891 symptom Diseases 0.000 claims description 17
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 16
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 13
- 239000012453 solvate Substances 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 9
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 8
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 8
- 210000003734 kidney Anatomy 0.000 claims description 6
- 210000002784 stomach Anatomy 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 230000036506 anxiety Effects 0.000 claims description 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 5
- 239000007789 gas Substances 0.000 claims description 5
- 150000007529 inorganic bases Chemical class 0.000 claims description 5
- 150000007530 organic bases Chemical class 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000014311 Cushing syndrome Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 206010036595 Premature delivery Diseases 0.000 claims description 4
- 230000005856 abnormality Effects 0.000 claims description 4
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 4
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims description 3
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- BESOQRFWCAJXLE-UHFFFAOYSA-N 2,3-bis(bromomethyl)-1,4-dimethoxybenzene Chemical compound COC1=CC=C(OC)C(CBr)=C1CBr BESOQRFWCAJXLE-UHFFFAOYSA-N 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- DPZNOMCNRMUKPS-UHFFFAOYSA-N resorcinol dimethyl ether Natural products COC1=CC=CC(OC)=C1 DPZNOMCNRMUKPS-UHFFFAOYSA-N 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 206010022489 Insulin Resistance Diseases 0.000 claims 3
- 206010010904 Convulsion Diseases 0.000 claims 2
- 230000002175 menstrual effect Effects 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- DWNAQMUDCDVSLT-UHFFFAOYSA-N diphenyl phthalate Chemical compound C=1C=CC=C(C(=O)OC=2C=CC=CC=2)C=1C(=O)OC1=CC=CC=C1 DWNAQMUDCDVSLT-UHFFFAOYSA-N 0.000 claims 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-M isobutyrate Chemical compound CC(C)C([O-])=O KQNPFQTWMSNSAP-UHFFFAOYSA-M 0.000 claims 1
- 229940127554 medical product Drugs 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- GMTCPFCMAHMEMT-UHFFFAOYSA-N n-decyldecan-1-amine Chemical compound CCCCCCCCCCNCCCCCCCCCC GMTCPFCMAHMEMT-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 40
- 239000000203 mixture Substances 0.000 description 30
- 108020003175 receptors Proteins 0.000 description 30
- 102000005962 receptors Human genes 0.000 description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 235000019439 ethyl acetate Nutrition 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- 239000000047 product Substances 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 239000002585 base Substances 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 229940126062 Compound A Drugs 0.000 description 8
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 8
- 108010041332 Very Late Antigen Receptors Proteins 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 239000003470 adrenal cortex hormone Substances 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 102400000059 Arg-vasopressin Human genes 0.000 description 6
- 101800001144 Arg-vasopressin Proteins 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 6
- 102000002852 Vasopressins Human genes 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229960003726 vasopressin Drugs 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 108010004977 Vasopressins Proteins 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000012429 reaction media Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000002686 anti-diuretic effect Effects 0.000 description 2
- 239000003160 antidiuretic agent Substances 0.000 description 2
- 229940124538 antidiuretic agent Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- MROCJMGDEKINLD-UHFFFAOYSA-N dichlorosilane Chemical compound Cl[SiH2]Cl MROCJMGDEKINLD-UHFFFAOYSA-N 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- XDLNRRRJZOJTRW-UHFFFAOYSA-N thiohypochlorous acid Chemical compound ClS XDLNRRRJZOJTRW-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- IILGKOHWDLRWOZ-UHFFFAOYSA-N 1,2-bis(1h-imidazol-2-yl)ethane-1,2-dione Chemical compound N=1C=CNC=1C(=O)C(=O)C1=NC=CN1 IILGKOHWDLRWOZ-UHFFFAOYSA-N 0.000 description 1
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- UHOPWFKONJYLCF-UHFFFAOYSA-N 2-(2-sulfanylethyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCS)C(=O)C2=C1 UHOPWFKONJYLCF-UHFFFAOYSA-N 0.000 description 1
- DTGZORBDGLEVNY-UHFFFAOYSA-N 2-propyloxolane Chemical compound CCCC1CCCO1 DTGZORBDGLEVNY-UHFFFAOYSA-N 0.000 description 1
- ZNHQFCJLFKKUNA-UHFFFAOYSA-N 5-sulfanylpentan-2-one Chemical compound CC(=O)CCCS ZNHQFCJLFKKUNA-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- VFGMADATNCKNSB-UHFFFAOYSA-N CC(C)CC1=CC=CC2=C1CC1=CC=CC=C21.Cl Chemical compound CC(C)CC1=CC=CC2=C1CC1=CC=CC=C21.Cl VFGMADATNCKNSB-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 108090000876 Oxytocin receptors Proteins 0.000 description 1
- 102000004279 Oxytocin receptors Human genes 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 206010038422 Renal cortical necrosis Diseases 0.000 description 1
- DHKSFFPYYHLQSU-UHFFFAOYSA-N SCCCCC(=O)CCCCS Chemical compound SCCCCC(=O)CCCCS DHKSFFPYYHLQSU-UHFFFAOYSA-N 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 108090000643 Vasopressin Receptors Proteins 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 201000003352 adrenal gland pheochromocytoma Diseases 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- RVOJTCZRIKWHDX-UHFFFAOYSA-N cyclohexanecarbonyl chloride Chemical compound ClC(=O)C1CCCCC1 RVOJTCZRIKWHDX-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000006612 decyloxy group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- LLLQJQUWSSBNHX-UHFFFAOYSA-N hydrazine 4-methylmorpholine Chemical compound CN1CCOCC1.NN LLLQJQUWSSBNHX-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000005430 kidney cortex necrosis Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N monofluoromethane Natural products FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- DGHUWPWPAXVRQG-UHFFFAOYSA-N n,n-didecylpyridin-4-amine Chemical compound CCCCCCCCCCN(CCCCCCCCCC)C1=CC=NC=C1 DGHUWPWPAXVRQG-UHFFFAOYSA-N 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- DAMMZEKMSLRRLN-UHFFFAOYSA-N phenyl chlorate Chemical compound O(C1=CC=CC=C1)Cl(=O)=O DAMMZEKMSLRRLN-UHFFFAOYSA-N 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
1274751 玖、發明說明: 【發明所屬之技術領域】 本發明係、關於醯氧基[%.定衍生物,其製備,及其治療 之應用。 根據本發明之化合物對於精胺酸-血管加壓素(Avp)之 VibX體或Vib及vla^體,具有親和力及選擇性。 【先前技術】
AVP為一種抗利尿作用及調節動脈壓作用著名之荷爾奪 八刺激成種文體· VjVbVib)及V2。這亟受體特別位灰 肝,(冠狀,腎,腦)血管,血小板,腎,子宮,腎上腺,膜 ,中樞神經系統,及腦垂體。因此,AVP具有心血管,肝 ,胰,抗利尿,及血小板凝集作用,及作用於中樞及周圍 神經糸統及子宮球。 各種文體之位置述於:s· JARD et al.,Vasopressin and oxytocin receptors: an overview, in Progress in Endocrinology. H_ IMURA and K· SHIZURNE ed·,Experta Medica,Amsterdam,φ 1988, 1 183-1188,亦述於下列文獻:j Lab Clin Med,1989, 111(6),617-632 及 Pharmacol. Rev·,1991,ϋ(1),73_i〇8。 更特定言之,AVP之Vla受體位於許多周圍器官及腦中。 彼專已經選殖,特別在鼠及人類,且彼等調節大部份AVp 之已知作用.血小板凝集;子宮收縮;血管收縮;酸固酮 ’皮貝醇’ C RF (親皮質素釋放因子),及親腎上腺皮質荷爾 蒙(ACTH)之分泌;肝糖分解,細胞增生,及AVp之主要中 樞作用(體溫過低,記憶,等)。 86164 1274751 vlb受體最初鑑定於各種動物(鼠,豬,牛,羊,等),包 括人類,之腦垂體腺性部(S· JARD et al., Mol· Pharmacol·, 1986, !〇_, 171-177; Y. ARSENIJEVIC et al·,J. Endocrinol·, 1994,141,383-391; J. SCHWARTZ et al·,Endocrinology, 1991, 129. (2)? 1107-1109; Y. DE KEYSER et al.5 FEBS Letters,1994, U15-220),彼等由AVP刺激親腎上腺皮質 荷爾蒙之釋放及加強CRF對於ACTH釋放之作用(G.E. GILLIES et al·,Nature,1982, 2^i,355)。在視丘下部中, Vlb 受體亦誘發 CRF之直接釋放(Neuroendocrine?logy,1994, 匕〇_,5 03-508),在這些方面涉及壓力之境遇。 這些Vlb受體已在大鼠(rats),人類,及小鼠(mice)選殖(Y. DE KEYSER,FEBS,Letters, 1994,356. 215-220; T. SUGIMOTO et al·,J· Biol· Chem.,1994, 26i (43), 27088-27092; M. SAITO et al·,Biochem. Biophys· Res. Commun·, 1995, 111 (3),751-757; S.J. LOLAIT et al.,Neurobiology, 1996? 92? 6783-6787; M.A. VENTURA et al.? Journal of Molecular Endocrinology,1999,2JL, 251-260),各種研究(當 場雜交,PCR(聚合酶鏈反應),等顯示這些受體遍及於各種 中樞組織(特別是腦,視丘下部,及腦垂體腺性部)及周圍組 織(腎,胰,腎上腺,心,肺,腸,胃,肝,腸系膜,膀胱 ,胸腺,脾,子宮,視網膜,甲狀腺,等)及在一些腫瘤( 腦垂體,肺,等),提出這些受體之廣泛生物學及/或病理學 角色及潛在涉及各種疾病。 例如,在鼠體内,研究已顯示AVP經由Vlb受體調節胰臟 1274751 之内分泌,刺激胰島素及葡萄朊(glueagon)之分泌(B. LEE et al.5 Am. J. Physiol. 269 (Endocrinal. Metab. 32): E1095-El 100,1995)或腎上腺髓質(其為AVP局部合成之位置)中兒 茶齡胺之產生(E. GRAZZINI et al.,Endocrinology,1996, 13_Z (a),3 906-3 914)。因此,在腎上腺組織中,AVP經由這 些受體在某些種類之腎上腺親鉻細胞瘤(其分泌AVP)中居 要角,誘發兒茶酚胺之大量產生,引起高血壓,對於血管 加壓素II受體拮抗劑及對於血管加壓素轉化酶抑制劑具有 抗性。腎上腺皮質亦富含Vla受體,涉及葡it類·皮質激素及 礦質類皮質激素(醛固酮及皮質醇)之產生。經由這些受體, AVP(循環或局部合成者)可誘發醛固酮產生,效力相當於血“ 管加壓素II (G· GUILLON et al·,Endocrinology,1995,136 (3),1285-1295)。皮質醇為壓力荷爾蒙ACTH產生之有力調 節劑。 最近之研究亦顯示腎上腺可經由髓質細胞所攜帶之v i b 及/或Vla受體之活化直接釋放crf及/或ACTH (G· φ MAZZOCCHI et al·,Peptides,1997,18 (2), 191-195; E. GRAZZINI et al·,J. Clin. Endocrinal· Metab·,1999,84 (6)) 2195-2203) 〇
Vlb受體亦被視為腫瘤標記。例如,分泌actH之腫瘤, 即某些腦垂體腫瘤,及某些支氣管癌(小細胞肺癌,SCLC) ’胰臟癌,腎上腺癌及曱狀腺癌,在一些情況包括庫辛氏 (Cushing丨s)徵候群(j· BeRThERAT et al·,Eur. J. Endocrinol·, 1996, 111,173; G.A· WITTERT et al·,Lancet,1990, 335, 86164 1274751 991-994; G· DICKSTEIN et al·,J. Clin. Endocrinol. Metab·, 1996, £±(8),2934-2941),過度表現Vlb受體。至於Vla受體 ,彼等為小細胞肺癌(SCLC)之較特異性標記(P.J. WOLL et al.,Biochem. Biophys. Res. Commun·,1989,164 (1), 66-73) 。因此,根據本發明之化合物顯然為診斷工具,提供這些 腫瘤增生之新穎治療方法及檢測方法,甚至在早期(放射標 示;SPECT.,單一光子發射電腦局部X射線檢法;pet SCAN ,正子發射局部X射線檢測掃描器)。
Vlb受體之傳信者大量存在於胃及腸中,;顯示Avp經由此 受體涉及胃腸道荷爾蒙如激膽囊素,胃泌素,或分泌素 (secretin)之釋放(τ· SUGIMOTO et al·, Molecular cloning and functional expression of Vlb receptor gene, in Neurohypophysis. Recent Progress of Vasopressin and Oxytocin Research; T. SAITO? K. KUROKAWA and S. YOSHIDA ed.,Elvesier Science,1995,409-413)。 國際專利申請案,〇 01/5513〇述及對於精胺酸-血管加壓 素之vlb受體,或Vib受體及Via受體,具有親和力及選擇性 之一族化合物。 更特定言之,Vlb受體之選擇性拮抗劑,氯 -l-[(2,4-二曱氧基苯基)磺醯基]_3_(2_甲氧基苯基)_2_氧基_ 2,3-一氫-1H-吲哚-3_基]_仁羥基-N,N-二曱基·2』比咯啶羧醯 胺左旋兴構物(下文稱為化合物Α),已述及(w〇〇1/5513〇; J. Pharmacol. Exp. The,5 2〇〇25 300 (3) 1122-1 130) 〇 【發明内容】- 86164 -10- 1274751 現在發現新穎化合物酿氧基D[t嘻唆衍生物對於精胺酸_ 血管加壓素之vlb受體,或vlb受體及Vla受體,具有親和力 及選擇性。 本發明之一主題為對應於下式(I)之化合物:
_ R!表一個氫原子,(Cl-c6)烷基,(CVC6)環烷基, -CH2CH2COOH或-nr2r3 ; -R2及R3各獨立表一個氫原子或(Ci-C6)烷基。 式⑴化合物包含三個不對稱碳原子;攜帶取代基_ CON(CH3)2之兔原子具有(s)組態,攜帶取代基之碳 原子具有(R)組悲,在D引卩朵酮第3位置之碳原子具有(r) 組態。 式(I)化合物可以鹼形式,或與有機或無機鹼之加成鹽形 式如14鹼金屬或鹼土金屬之鹽,或與有機或無機胺之鹽 形式存在。該加成鹽為本發明之一部分。 這些鹽有利以醫藥可接受之鹼製備’但是其他可用於例 如純化或分離式⑴化合物之驗之鹽亦為本發明之一部分。 86164 -11 - 1274751 式(i)化合物可以水合物或溶劑化物之形式,即與一或多 個水分子或與-種溶劑組合或合併之形式存在。該水合物 及〉谷劑化物亦為本發明之^ 部分。 術β吾纟兀基」意為1至6個碳原子之直鏈或分支之烷基, 如甲基,乙基,丙基,異丙基,丁基,異丁基,第三丁基 ,戊基,異戊基,己基,或異己基。 術^環&基」意為3至6個碳原子之環完基,如環丙基 ,環丁基’環戊基,或環己基。 在本發明主題之式⑴化合物中,可提及之較佳化合物定❿ 義如下: -h表一個氫原子,甲基,乙基,異丙基,環己基,-_CH2CH2COOH,胺基,或二甲基胺基;呈驗形式,或與 有機或無機鹼之加成鹽形式,及水合物或溶劑化物形式。 在本發明主題之式(I)化合物中,特別可提及下列化合物: -(3R,5S)-l-[(3R)-5-氯- l-[(2,4-二甲氧基苯基)磺酿基]-3-(2-甲氧基苯基)-2-氧基-2,3-二氫-1H-吲哚—3-基]-5-[(二 _ 甲基胺基)羰基]-3-吡咯啶基醋酸酯; -(3R, 5S)-l-[(3R)-5-氯-l-[(2,4-二曱氧基苯基)石黃酿基]-3· (2-曱氧基苯基)-2-氧基-2,3_二氫-1H-吲哚-3-基]-5_[(二 甲基胺基)羰基]-3-吡咯啶基丙酸酯; • (3R,5S)-1-[(3R)_5-氯-l-[(2,4-二曱氧基苯基)磺醯基]-3-(2-曱氧基苯基)-2-氧基-2,3-二氫-1H-吲哚-3-基]-5-[(二 曱基胺基)羰基]-3-吡咯啶基甲酸酯; -(3R,5S)-l-[(_3R)-5-氯-l-[(2,4-二甲氧基苯基)磺醯基]-3- 86164 -12- 1274751 (2-甲氧基苯基)-2-氧基-2,3-二氫-1H-吲哚-3-基]-5-[(二 曱基胺基)羰基]-3-吡咯啶基環己羧酸酯; -(3R,5S)-l-[(3R)-5-氯小[(2,4-二甲氧基苯基)石黃醯基 (2-甲氧基苯基)-2 -氧基-2,3 -二氫-1H-D引D朵-3-基]二 甲基胺基)被基]-3 - D比洛σ定基2 -甲基丙酸g旨; • 4-[[(3R,5S)-l-[(3R)-5-氯-1-[(2,4-二甲氧基苯基)石黃醯基 ]一3_(2-甲氧基苯基)-2 -氧基- 2,3 -二氯-1Η- D弓丨Π朵-3-基]一 二甲基胺基)羰基]-3-D比咯啶基]氧基]-4-氧基丁酸; (28,411)-4-[(胺基羰基)氧基]-1-[(311)-5-:氯-1-[(2,4-二曱 氧基苯基)磺醯基]-3-(2-甲氧基苯基)-2-氧基-2,3-二氫_ 1H-吲哚-3-基]-N,N-二甲基-2-吡咯啶羧醯胺; _ (2S,4R)_4-[[(二甲基胺基)羰基]氧基:hl-[(3R)-5-氯-1-[(K二曱氧基笨基)磺醯基]_3-(2-甲氧基苯基)_2_氧基_ 2,3_二氫_1H_吲哚_3-基]-Ν,Ν-二甲基-2-吼咯啶羧醯胺; 王驗形式’或與有機或無機驗之加成鹽形式,及水合物 或溶劑化物形式。 根據另一方面,本發明之一主題為一種製備式(I)化合物 之方法,其特徵在於: 下式之(2S,4RH_[5H[(2,4-二甲氧基苯基)磺醯基]-(2·曱氧基笨基)义氧基-2,3-二氫-lH-口引D朵j基]冬羧基-一甲基-2-口比。各咬叛酸胺,左旋異構物: 86164 -13- 1274751
(化合物A) 與下式之酸之s能基衍生物反應 〇
II HO-C-R! (II) 其中R1如式⑴化合物定義。 式(I)化合物選擇性轉化為其與鹼之一種加成鹽。 式(II)之酸之官能基衍生物可使用醯基氯,酐,或 本身。 當使用一種醯基氯時,反應係在一種溶劑,如氯化溶劑 ’如二氯曱烷,二氯乙烷,或氯仿,醚,如四氫呋喃,: 氧六圜’或醯胺,如ν,ν-二甲基甲醯胺中,在— χ 1 你 種驗,如 三乙胺,Ν-甲基嗎啉,吡啶,4_二甲基胺基吡啶,或 二異丙基乙胺存在下,在-6(TC至周圍溫度間之溫度進行。 當使用一種酐時,反應係在一種鹼如吡啶或4 V ~^ T暴胺 基)吡啶存在或不存在下,在一種溶劑中,或在溶劑不存在 下,在周圍溫度至反應介質之回流溫度,間之溫度進行。合 使用一種溶劑時,該溶劑可選自氣化 田 ⑴ —氟甲燒, 及芳族溶劑,如甲苯。 式⑴中I表-C^CH'OOH之化合物亦可由化合物a與琥 86164 -14- 1274751 珀酸酐在一種鹼如咄啶存在下,在一種溶劑_,或在溶劑 不存在下,在周圍溫度至反應介質之回流溫度間之溫度進 行0 畜使用酸本身時,反應係使用一種縮合劑,如碳化二亞 胺,例如1,3-二環己基碳化二亞胺或丨,3_二異丙基碳化二亞 胺,或咪唑,例如丨,广草醯基二咪唑或n,n、羰基二咪唑進 行。反應係在一種鹼,如三乙胺,N,N_二異丙基乙胺,吡 啶,4-二甲基胺基吡啶,或N_甲基嗎啉存在或不存在下, 在一種溶劑,如一種氯化溶劑,例如二氯_烷,二氯乙烷 ,或氯仿,一種酯,例如醋酸乙酯,一種轉,例如乙醚, 丙峻四氫咲喃,或二氧六圜,一種腈,例如乙腈, :種醯胺,例如N,N-二甲基甲醯胺,或一種芳烴,例如甲 苯或二甲苯中,在_2〇。〇至8〇。〇間之溫度進行。 當使用酸本身時’反應亦可在-種酸催化劑,如-種無 機酉夂例如鹽g夂,氫漠酸,或硫酸,一種有機酸,例如醋 酸’甲酸’草酸’或對1苯績酸,或—種路易⑷ 酸’例如三氯化硼,三氟化硼,或三溴化硼存在下進行。 反應係在一種溶劑,如氯化溶劑,例如二氯曱烷,二氯乙 烷’或氯仿’ 一種醚,例如乙醚,二異丙醚,日氫呋喃, :二氧陸圜,-種酮,例如丙酮,曱基乙基丙酮,或曱基 兴丁基酮,一種腈,例如乙腈,或一種醯胺,例如 曱基曱t 中’在〇 c至溶劑之回流溫度間之溫度進行。 式⑴中〜表-個氫原子之化合物亦可由化合物A血甲奶 在醋酸酐及-種驗如^定存在下在代至周圍溫度間之= 86164 -15- 1274751 度製備。 根據該方法之一種變異,當R〗表-NR2R3時: a)化合物A在一種鹼存在下與氯甲酸苯酯反應以獲得下 式之化合物B :
b)化合物Β與下式之化合物反應 HNR2R3 (III) 其中R2及I如式⑴化合物定義,以獲得式⑴中r严NR2R3之 化合物。 在步驟a)中’化合物A與氯曱酸苯酯在一種鹼如吡啶或三 乙胺存在下,在一種溶劑如二氣曱烷中,或無溶劑,在0^ 至100°C間之溫度反應。 在步驟b)中,化合物b與式(ΙΠ)化合物之反應係在一種溶 劑如二氯曱烷或四氫呋喃或這些溶劑之混合物中,在_60。〇 至溶劑之回流溫度間之溫度進行。 然後所獲得之式(I)化合物可由反應介質分離,並根據習 知方去例如結晶或層析純化。 86164 ' 16 - 1274751 之方法製備。 ,已知,或根據 化合物A係根據申請案W〇Ο 1/55 130中所述 式(II)之酸之官能基衍生物為商業上可得 已知方法製備。 根據另一方面,本發明之主題亦為化合物Β。此化合物用 作式⑴中RfNR^R3之化合物之合成中間物。 【實施方式】 下列實例述及根據本發明之一些化合物之製備。這些實 例並非限制,僅例示本發明。實例中所示化合物之號碼為 下表中所示者,該表顯示根據本發明之一“化合物之化學 結構及物理性質。 子 在實例中,使用下列簡寫:
EtOAc :醋酸乙酯 鱗:乙謎 異醚:二異丙基醚 DCM :二氯甲烷 Μ·ρ·:熔點 AT :周圍溫度 Β.ρ·:沸點 Η P L C ·南性能液態層析 質子磁力共振光譜NMR)係在d6_DMS0中於2〇〇 ΜΗζ 記錄,使用d6-DMSQ峰作為參考。化學位移5係以每百萬 份之份數(ppm)表示。所測得之訊號表示為:s :單重線; bs:寬單重線;d:二重線;dd:雙二重線;t:三重線;^ :四重線;up :未解析之峰;mt :多重線。 86164 -17- 1274751 NMR光譜確認化合物之結構。 貫例1 :化合物1 (3R,5S)-l-[(3R)-5 -氯- l- [(2,4-二曱氧基苯基)石黃酸基]-、(二、 曱氧基本基)-2-氧基- 2,3 -二氫_1Η_Π引Π朵-3-基][(二曱基胺 基)羰基]-3-吡咯啶基醋酸酯 (I) : r1=-ch3 30克(2S,4R)-l-[5-氯-l-[(2,4-二甲氧基苯基)磺醯基]·3、 (2_甲氧基苯基)-2_氧基-2,3-二氫]Η-吲哚_3_基]-4-Μ基、 Ν,Ν-二曱基-2-吼咯啶羧醯胺,左旋異構物|化合物Α),145 克4-(二甲基胺基)fi比啶,及3〇〇毫升醋酸酐之混合物回流2 小時30分鐘。在反應混合物冷卻至周圍溫度後,17〇毫升絕 對乙醇加入。混合物在真空下濃縮,殘餘物以1 〇⑽毫升 EtOAc萃取,有機相以67〇毫升飽溶液洗,以
NaHC〇3水溶液洗二次,溶劑在真空下蒸發移除。殘餘物吸 收入190毫升2_丙醇中’混合物回流,然後冷卻至周圍溫度 作匕合物在真空下遭、縮,殘餘物吸收入異鍵中 〜"^、、、口日日 克所欲產物,熔點=194-195¾ 所形成之、、Ό M產物旋轉濾出,以異醚洗,乾燥。獲得30.28 25 a :-133.9° (c=〇.5 ;乙腈 H NMR: d6_DMSQ: δ (ppm)n2 & up i3H; m ^ 3-7: s:3H; 3.9: S:3H; 4.6: 5.2: 6.6^8 up: 10H。 … 實例2 ··化合物2 ,S) 1 [(3R)-5、氯小[(2,4_二甲氧基苯基)石黃醯基卜 86164 -18- 1274751 甲氧基苯基)-2-氧基-2,3-二氫_1H-吲哚_3_基]_5_[(二甲基胺 基)幾基]-3 - D比嘻σ定基丙酸酯 、 (I) : Rj-- CH2CH3 5克化合物A,0.24毫升4-(二曱基胺基)吡啶,及5〇毫升丙 酸酐之混合物回流2小時30分鐘。在反應混合物冷卻至周圍 溫度後,28毫升絕對乙醇加入。混合物在真空下濃縮,殘 餘物以60毫升Et0Ac萃取,有機相以1〇〇毫升飽和NaCi水溶 液洗,以Π0毫升10% NaHC〇3水溶液洗三次,溶劑在真空 下蒸發移除。殘餘物吸收入異醚中’所形崴之沉澱物旋轉 濾出。獲得4.31克所欲產物。a25D=_1〇r(c = 〇.5 ;乙腈)。 !H NMR: d6-DMSO: δ (ppm): 〇.95: t: 2h; 1.6^2.7: Up: 12H; 3.3: bs:3H; 3.6: s:3H; 3.8: S:3H; 4.5: 5.15 mt: 1H; 6.6至 8.2: up: 11H。 實例3 :化合物3 (3R,5S)_W(3R)_5氯小[(2,4_二甲氧基苯基)雜基]·3_(2_ 曱氧基苯基卜之-氧基-之一-二氫-^-吲哚—^基卜^“二甲基胺 基)魏基]-3 - a比嘻咬基甲酸酯
(I) : R^H 4¾升甲酸冷卻至Gt,1.6毫升酷酸酐逐滴加人,混合物 在低於聊之溫度授拌4小時。反應混合物在冰浴中冷卻, 0.63克化合物A於7毫升吼咬中之溶液在5分鐘内加人,混合 物先乾燥’在冰浴中冷卻,在周圍溫度搜拌48小時。水加 入反應混合物中,以Et〇Ae萃取,有機相以水及飽和_ 溶液洗,以Na2S〇4乾燥,溶劑在真空下蒸發移除。殘餘物 86164 -19- 1274751 在矽膠上層析,以DCM/EtOAc混合物(70/30;體積/體積) 溶離。獲得0.27克所欲產物。在DCM/異醚混合物(80/20 ; 體積/體積)中固化後,獲得所欲產物,呈粉末形式,含有0.5 莫耳異,溶點=12 7 °C。 α = (c = 0.11 ;氯仿)。 實例4 :化合物4 (3R,5S)-l_[(3R)-5-氯-l-[(2,4-二甲氧基苯基)磺醯基]-3-(2-甲氧基苯基)-2-氧基-2,3-二氫-1H-吲哚-3-基]-5-[(二甲基胺 基)羰基]-3-吡咯啶基環己羧酸酯 [
1,5克化合物八,0.6304毫升環己烷羰基氯,〇.62克队>^ 二異丙基乙胺,及4-(二甲基胺基)[I比啶之一些結晶於2〇毫升 DCM中之混合物在周圍溫度攪拌8天。混合物在真空下濃縮 ,殘餘物吸收入EtOAc/水混合物中,混合物由加入固體 NaHC03鹼化,以沉降分離,有機相以飽和反2€〇3溶液及飽 和NaCl溶液洗二次,以ν〜8〇4乾燥,溶劑在真空下蒸發移 除。殘餘物在石夕膠上層析,以EtQAc/DCM混合物(80/20 ; 體積/體積)溶離。所獲得之產物吸收入5毫升異醚中,在周 圍溫度攪拌48小時,所形成之沉澱物旋轉過濾,獲得1.0克 所欲產物,熔點=197_198r。旋轉過濾之液體在真空下濃 縮,所獲得之固體由DCm/異醚混合物中結晶。再獲得0·9 克所欲產物’、呈結晶形式,熔點=197_2〇(rc。 86164 -20- 1274751 a 25D = -144° (c = 0.18 ;氯仿)。 實例5 :化合物5 (3R,58)-1-[(311)-5_氯-1-[(2,4-二甲氧基笨基)績醯基]小(2_ 甲氧基苯基)-2-氧基-2,3-二氫-1H-吲哚_3-基]_5__[(二甲基胺 基)幾基]-3 - 口比咯σ定基2 -甲基丙酸酉旨 (I) : R,- CH(CH3)2 1.5克化合物八,0.75毫升異丁醯氯,及122克沭1^_二異丙 基乙胺於20*升DCM中之混合物在周圍溫度攪拌36小時。 混合物在真空下濃縮,殘餘物吸收入水+,由加入固體 NaHC〇3鹼化,以Et0Ac萃取,有機相以水洗,以Na2S〇4乾 爍,溶劑在真空下蒸發移除。殘餘物在矽膠上層析,以 DCM/EtOAc混合物(70/30 ;體積/體積)溶離。在Et〇Ac/異醚 混合物中固化後,獲得1.17克所欲產物,熔點=183-185〇c。 a 25D=-172° (c=0.15 ;氯仿)。 實例6 :化合物6 4-[[(3R,5S)-l-[(3R)-5-氯-l-[(2,4-二曱氧基苯基)石黃醯基μ 3-(2-曱氧基苯基)-2-氧基-2,3-二氫-1H-D弓丨哚-3-基]-5-[(二曱 基胺基)羰基]-3-吡咯啶基]氧基]-4-氧基丁酸 (I) : R!=- ch2ch2cooh
〇·2克化合物a,0.2克琥珀酸酐,及3毫升吡啶之混合物 在50°C加熱5分鐘至溶解,在25°C攪拌20小時。混合物在真 空下濃縮,殘餘物吸收入2N HC1溶液中,以醚萃取,以沉 降分離’有機相中所形成之沉澱物旋轉過濾,以醚洗。獲 得0·2克所欲產-物,呈結晶形式,熔點=225-228°C 86164 -21 - 1274751 a 25D=-252° (c=0.25 ;氯仿)。 iH NMR: d6-DMSO: δ (ppm): 1.6至 1.9: up: 2H; 2.2至 2·6: 叩:12%3.0至3.4:55:311;3.5至3.7:53:311;3.7至3.9:53: 3印4.4至4.6:叩:111;5.1至5.3:叩:1?1;6.6至7.0:叩:5出 7.26: t: 1H; 7.39: dd: 1H; 7.6JL7.8: up: 2H; 7.94: d: 1H; 12.0: bs: 1H。 實例7 :化合物7 (2S,4R)-4_[(胺基羰基)氧基]-i-[(3R) — 5-氯-i-[(2,4-二甲氧· 基笨基)磺醯基]-3-(2-曱氧基苯基)-2-氧基h,3-二氫-1H-吲 哚·3·基]·Ν,Ν_二曱基-2_吡咯啶羧醯胺 (I) · R^- NH2 . (A) (2S,4R)-4-[(苯氧基羰基)氧基]小[(3R)-5-氯小[(2,4-二 _ 甲氧基苯基)磺醯基]-3-(2-甲氧基苯基)-2-氧基-2,3-二氫_ 1H-D引哚_3_基]-N,N-二曱基-2-吡咯啶羧醯胺 4宅升氣甲酸本酯在25 °C加入1.6克化合物A於20毫升口比 唆中之溶液内,混合物在25°C攪拌20小時。反應混合物在籲 真空下濃縮,殘餘物吸收A1N HC1溶液中,以EtOAc萃取 ’有機相以NajO4乾燥,溶劑在真空下蒸發移除。在異醚 中滴定後’獲得1.23克所欲產物,熔點=i15-125°c (B) (2S,4R)-4-[(胺基羰基)氧基]小[(3R)-5'氣+[(2,4_ 二甲 氧基苯基)磺醯基]-3-(2-甲氧基苯基)-2-氧基_2,3_二氫“ H_ 吲哚-3-基]-N,N-二曱基_2_吼咯啶羧醯胺 〇.7克上一步驟所獲得之化合物於15毫升ΤΗΤ中之溶液冷 部至-6(TC,4克ΝΗ3氣噴射加入,混合物攪拌5小時,使溫 86164 -22- 1274751 度回至o°c並保持。反應混合物在真空下濃縮,殘餘物在 矽膠上層析,以DCM及然後以EtOAc溶離。在異醚中滴定 後,獲得〇·37克所欲產物,熔點155-165。(:。 Λ 25D=-184 (c=0.25,氣仿)。 實例8 :化合物8 (2S,4R)-4-[[(二甲基胺基)魏基]氧基]小氯小[(2,4_ 二曱氧基苯基)磺醯基]-3-(2-甲氧基苯基)-2-氧基-2,3-二氫-1H-吲哚-3-基]_n,N-二甲基-2-吼咯啶羧醯胺 ⑴:n(ch3)2 ; 0·35克貫例7步驟a中所獲得之化合物及二甲胺於THF中 之2M溶液10毫升之混合物在25°C攪拌20小時。反應混合物 在真空下濃縮,殘餘物於異醚中在加熱條件下碟製,所形 成之沉殺物旋轉過濾。獲得0.1 8克所欲產物,熔點=138-140 〇C。 a25D 叫 52。(㈣·25;氣仿)。 下表㉙示根據本發明之化合物之一些實例之化學結構及 物理性質。
表I
86164 -23- 1274751 化合物號碼 Ri 熔點t 結晶溶劑 a 25d= (氯仿) 1 —-- -ch3 194-195 異醚 -133.9。(c = 0.5;乙腈) 2 -ch2ch3 異醚 -107。(c = 0.5;乙腈) 3 —---- Η 127 DCM/異醚 -173° (c=0.11) 4 --- Ό 197-200 DCM/i異醚 -144° (c=0.18) 5 -ch(ch3)2 183-185 EtOAc/異 _ -172° (c = 0.15) 6 --—---- -ch2ch2cooh 225-228 醚 -252° (c = 0.25) 7 —^___ -nh2 155-165 異醚 -184° (c = 0.25) 8 --·~---- N(CH3)2 138-140 異醚 152。(c = 0.25) 根據本發明之化合物為生物化學研究之主題。 根據本發明之式⑴化合物對於精胺酸_血管加壓素之vib 受體之親和力係在活體外使用Y. DE KEYSER et al.,Febs Letters’ i 994,现,2 15_22〇中所述之方法測定。此方法包括 =究活體外礙製之精胺酸·血管加Μ([3Η]_Ανρ)置換攜帶 鼠或人類Vlb受體之細胞或腦垂體腺性部膜製劑 : 、受體。根據本發明之化合物抑制5嶋製之精胺酸-血管 86164 -24- 1274751 加麈素結合之灌疮 、又(1(25())—般低於5.〇乂1〇-9]^。例如,實例1 化合物對於人類Vib受體之〜為3·4χΐ〇·9Μ。 、 心雕據本么明之式⑴化合物對於精胺酸-血管加壓素之Via 又版之親和力係在活體外使用M. THIBONNIER et al.,J· 、勹 ·’ 1994, Μ,3304_331〇中所述之方法測定。此方 法=研究活體外礙製之精胺酸_血管加壓素(阳_請)置 換‘ Τ乳或人頰Via受體之細胞或膜製劑上存在之Via受體 -弋()化3物對於精胺酸_血管加塵素之受體具有 ’見^力1C5G為值為10.8鼠級。例如,實例1;化合物對於人類 Vla受體之 IC5G為 8.4xl〇-8M。 先月'J技藝之化合物A對於人類〜受體之工〜為i 〇8M ,對於人類Vla受體之1〇5。為3上1〇.71^。 亦研九根據本發明之式⑴化合物對於血管加壓素之乂2受 體之親和力(以 M. Birnbaumer et al,Nature (Lond),1992, li2, 333-335中所述之方法)e所研究之化合物對於%受體 具有極少或無親和力。 因此,根據本發明之化合物可用於製備醫藥產物,特別 是用於預防或治療任何涉及精胺酸_血管加壓素及/或其Vib 受體,或其vlb及Vla受體之病理症狀之醫藥產物。 lb 根據本發明之另一方面,本發明之主題為醫藥產物,其 包含一種式(I)化合物,或其與一種醫藥可接受鹼之加成鹽 ’或一種式(I)化合物之溶劑化物或水合物。 根據本發明之化合物可用於治療或預防人類或動物之各 種血官加壓素·依賴性症狀,如心血管症狀,例如高血壓, 86164 -25 - 1274751 肺高血壓,心臟官能不足,心肌梗塞,或冠狀動脈血管瘦 攣,特別在吸煙者,雷諾氏(Raynaud’s)病,及不穩定之絞 痛’及PTCA(經皮經管腔之冠狀血管形成術),心臟絕血, 或止血障礙;中樞神經系統之症狀,如偏頭痛,腦血管痙 攣,腦出血,腦水腫,抑鬱,焦慮,壓力,感情違常,強 迫觀念-強迫行為達常,恐懼發作,精神狀態或記憶違常; 腎系統之症狀,如腎血管痙攣,腎皮質壞死,或腎原之尿 朋病’月糸統之症狀,如胃血管瘦攣,肝之硬變,潰癌, 或嘔吐之病理,例如噁心,包括由於化學诒療或旅行病之 σ惡心;或糖尿病性腎病。根據本發明之化合物亦可用於治 療性行為之違常;在婦女,根據本發明之化合物可用於治 療無月經(dismenoirhoea)或過早分娩。根據本發明之化合 物亦可用於治療小細胞肺癌;血鈉過少性腦病;肺徵候群 ’梅尼艾氏(Meniere’s)病;青光眼;白内障;肥胖症;第I! t糖尿病,動脈粥瘤硬化症·,庫辛氏徵候群;騰 島素抗性;或高三酸甘油酯血症;或手術後治療,特別在 腹部外科手術後。 根據本發明之化合物亦可用於治療或預防任何由於壓力 產生之病理學症狀,如疲勞及其徵候群,ACTH依賴性疾病 ,心臟病,疼痛,胃排空,糞排泄(結腸炎,過敏性腸徵候 群,或克隆氏(Crohn,s)病),或酸分泌之變化,高血糖症, 免疫抑制,發炎病變(類風濕性關節炎及骨關節炎),多重感 木癌症,氣喘,牛皮癖,過敏,及各種神經精神病,如 神經性厭f,.貪食症,心境違常,抑鬱,焦慮,睡眠違常 86164 -26- 1274751 ,恐懼狀態,恐怖症,強迫觀念,痛感違常(纖維肌痛),神 經變性疾病(阿滋海默(Alzheimer,s)症,巴金森氏(Parkinson,s) 症’或予丁頓氏(Huntingdon’s)疾病),藥癮,出血壓力,肌 肉痙攣,或低血糖症。根據本發明之化合物亦可用於治療 或預防慢性壓力症,如免疫抑制,不孕問題,或視丘下部_ 腦垂體-腎上腺軸之功能不良。 根據本發明之化合物亦可用作精神刺激劑,造成對於周 圍之警戒或感情反應性增加,及較容易適應。 根據另一方面,本發明係關於醫藥組合物,包含一種根 據本發明之化合物作為活性成份。這些醫藥組合物含有有 效量之至少一種根據本發明之化合物,或該化合物之醫藥 可接叉體’溶劑化物,或水合物,及至少一種醫藥可接受 之賦形劑。 該賦形劑,依據所欲醫藥形式及施用方法,係選自熟習 技藝人士周知之普通賦形劑。 在經口,經舌下’經皮下,經肌肉Μ,經靜脈内,局部 ’/經氣管内’經鼻内,、經皮,或經直腸施用之本發明之醫 藥組合物中,上述式⑴之活性成份,或其鹽,溶劑化物西 或水合物可以與習知醫藥賦形劑之混合物之單劑施用形式 把用於動:及人類’用於預防或治療上述違常或疾病。 適合之%劑施用形式包含經口施用之形式,如錠,軟或 硬明膠膠囊,粉末,顆粒,及口服溶液或懸浮液,經舌下 ,經頰,、敏氣管内,經眼内,或經鼻内施用之形式,吸入 施用之形式,局部,經皮,經纟 、、二肌肉内,或經靜脈 86164 -27· 1274751 内%用之形式’經直腸施用及植入之形式。對於局部施用 ’根據本發明之化合物可以乳膏,凝膠,軟膏,或洗劑使 用。 例如,根據本發明化合物之單劑施用形式,錠形式,可 包含下列成份: 根據本發明之化合物 5 0. 〇毫克 甘露糖醇 223·75毫克 父聯叛甲基纖維素croscaramellose納 6.0毫克 玉米澱粉 U 5.0毫克 髮基丙基甲基纖維素 2 · 2 5毫克 硬脂酸鎂 1 η古士 經口施用,每天所施用之活性成份之劑量可達〇〇1至工⑽ 笔克/公斤,以一或多劑施用,較佳為〇 〇2至50毫克/公斤。 特別之情況適合使用較高或較低劑量;該劑量不偏離本 發明之範圍。根據一般實施,適合各病人之劑量係由醫生 根據施用之方法及病人之重量及反應決定。 根據另一方面,本發明亦關於一種治療上述病理學症狀 之方法,其包含施用有效劑量之一種根據本發明之化合物 ’或其醫藥可接受鹽或水合物或溶劑化物之一於病人。 86164 -28-
Claims (1)
- 月日修(更)正本 __ —4·374^5^19736號專利申請案 文申請專利範圍替換本(95年7月) 格、申請專利範圍: 1. 一種對應於下式(I)之化合物:其中: -K表氫原子,(CVC6)烷基,(C3-C6)環烧基, -CH2CH2COOH之基或-NR2R3之基; _ R2及R3各獨立表氫原子或(CVC6)烷基; 呈鹼形式,或與有機或無機鹼之加成鹽形式,及水合物 或溶劑化物形式。 2. 根據申請專利範圍第1項之式⑴化合物,其中1表氫原子 ,曱基,乙基,異丙基,環己基,-CH2CH2COOH之基, 胺基,或二甲基胺基; 呈鹼形式,或與有機或無機鹼之加成鹽形式,及水合 物或溶劑化物形式。 3. 一種化合物,其係選自下列: -(3R,5S)-l-[(3R)-5-氯-1-[(2,4-二曱氧基苯基)磺醯基 86164-950719.doc 1274751 ]-3-(2-甲氧基苯基)-2-氧基-2,3-二氫-1Η_Θ卜朵-3-基 ]-5-[(二甲基胺基)幾基]-3-ρ比洛淀基醋酸g旨; · -(3R,5S)-l-[(3R)-5-氣-1-[(2,4-二甲氧基苯基)磺醯基 ]-3-(2-甲氧基苯基)-2-氧基-2,3-二氫_1Η4卜朵-3-基 ]-5-[(二甲基胺基)幾基]-3-ρ比洛淀基丙酸g旨; -(3R,5S)小[(3R)-5-氣-1_[(2,4-二甲氧基苯基)磺醯基 ]-3-(2-甲氧基苯基)-2-氧基-2,3-二氫-1H-Θ丨嗓-3-基 ]-5-[(二甲基胺基)魏基]-3 -峨洛唆基甲酸_ ; -(3R,5S)_l-[(3R)-5_ 氯 _1_[(2,4_ 二甲氧基苯基)磺醯基 φ ]-3-(2_甲氧基苯基)-2-氧基-2,3-二氫_1Η_4卜朵-3-基 ]-5-[(二甲基胺基)羰基]-3-吡咯啶基環己羧酸酯; -(3R,5S)-l-[(3R)-5 -氣·1-[(2,4_二甲氧基苯基)石夤酸基 ]-3-(2•甲氧基苯基)-2-氧基-2,3-二氫-1Η-吲哚_3_基 ]-5-[(二甲基胺基)裁基]-3-p比洛咬基2 -甲基丙酸酯; -4-[[(3R,5S)_l-[(3R)-5 -氣-1_[(2,4-二曱氧基苯基)石黃醯 基]-3-(2-曱氧基苯基)-2-氧基-2,3-二氫-1H-吲哚-3-基 ]-5-[(二曱基胺基)羰基]-3-吡咯啶基]氧基]-4-氧基丁酸; ® -(2S, 4R)_4-[(胺基幾基)氧基]_i_[(3R)_5 -氯小[(2,4_二 甲氧基苯基)磺醯基]-3-(2-甲氧基苯基)-2-氧基-2,3-二 氫-1H-K丨哚-3-基]-N,N-二甲基-2-峨咯啶羧醯胺; -(2S,4R)-4-[[(二曱基胺基)魏基]氧基]氣 -1-[(2,4-二曱氧基苯基)石黃醯基>3_(2-甲氧基苯基)_2_ 氧基-2,3-二氫-1H-吲哚-3-基]-N,N-二甲基-2-吡咯啶羧 酸胺;呈驗形式,或與有機或無機鹼之加成鹽形式, 86164-950719.doc -2- 1274751 及水合物或溶劑化物形式。 一種製備根據申請專利範圍第1項之式(I)化合物之方法 ,其特徵在於: 下式之(2S,4R)-l-[5-氣-1_[(2,4-二甲氧基苯基)績醯基 ]_3-(2 -甲氧基苯基)-2-氧基- 2,3-二氫_1H-1卜朵_3_基]-4-經 基-N,N-二曱基-2-吡咯啶羧醯胺,左旋異構物:與下式之酸之官能基衍生物反應 HO-C-R1 (Π) 其中I如申請專利範圍第1項之式⑴化合物定義。 一種製備根據申請專利範圍第1項之式(I)化合物之方法 ’其中1^表,112113之基,其特徵在於: a)如申請專利範圍第4項中定義之化合物a,在鹼存在下 與氣曱酸苯酯反應,以獲得下式之化合物B : 86164-950719.doc 1274751b)化合物B與下式之化合物反應 HNR2R3 (III) 其中R2及R3如申請專利範圍第1項之式(I)化合物定義,以 獲得式(Ι)*Ι^=ΝΙ12Ι13之化合物。 6· —種下式之化合物:OCH3 一種用於治療心血管症狀、壓力、焦慮、抑鬱、強迫觀 念-強迫行為違常、恐懼發作、腎系統之症狀、胃系統之 症狀、小細胞肺癌、肥胖症、第〗型及第„型糖尿病、胰 島素抗性、高三酸甘油酯血症、動脈粥瘤硬化症'庫辛 86164-950719.doc -4- 1274751 氏(Cushing’s)徵候群、無月經(dismenorrhoea)及過早分娩 之醫藥產物’其特徵在於包含根據申請專利範圍第1至3 項中任一項之式⑴化合物,或式⑴化合物與醫藥可接受 鹼之加成鹽,或式(I)化合物之水合物或溶劑化物。 8· 一種用於治療心血管症狀、壓力、焦慮、抑鬱、強迫觀 念-強迫行為違常、恐懼發作、腎系統之症狀、胃系統之 症狀、小細胞肺癌、肥胖症、第I型及第π型糖尿病、胰 島素抗性、高三酸甘油酯血症、動脈粥瘤硬化症、庫辛 氏(Cushing’s)徵候群、無月經(dismenorrhoea)及過早分娩 之醫藥產物,其特徵在於包含根據申請專利範圍第1至3 項中任一項之式(I)化合物,或此化合物之醫藥可接受鹽 ,水合物,或溶劑化物,及至少一種醫藥可接受之賦形 劑。 9· 一種根據申請專利範圍第1至3項中任一項之式⑴化合物 之用途,其係用於製備醫藥產物以治療心血管症狀,壓 力,焦慮,抑鬱,強迫觀念-強迫行為違常,恐懼發作, 月糸統之症狀’胃系統之症狀,小細胞肺癌,肥胖症, 第I型及第II型糖尿病,胰島素抗性,高三酸甘油酯血症 ,動脈粥瘤硬化症,庫辛氏(Cushing,s)徵候群,無月經 (dismenorrhoea)及過早分娩。 86164-950719.doc
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0209242A FR2842527B1 (fr) | 2002-07-19 | 2002-07-19 | Derives d'acyloxypyrolidine, leur preparation et leur application en therapeutique |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200410957A TW200410957A (en) | 2004-07-01 |
TWI274751B true TWI274751B (en) | 2007-03-01 |
Family
ID=29797610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092119736A TWI274751B (en) | 2002-07-19 | 2003-07-18 | Acyloxypyrrolidine derivatives, preparation thereof and application thereof in therapeutics |
Country Status (28)
Country | Link |
---|---|
US (1) | US7202267B2 (zh) |
EP (1) | EP1525198B1 (zh) |
JP (1) | JP4264414B2 (zh) |
CN (1) | CN100425608C (zh) |
AR (1) | AR040571A1 (zh) |
AT (1) | ATE312092T1 (zh) |
AU (1) | AU2003271815B8 (zh) |
BR (1) | BR0312800A (zh) |
CA (1) | CA2492224A1 (zh) |
DE (1) | DE60302670T2 (zh) |
DK (1) | DK1525198T3 (zh) |
EA (1) | EA008444B1 (zh) |
ES (1) | ES2254962T3 (zh) |
FR (1) | FR2842527B1 (zh) |
HK (1) | HK1074444A1 (zh) |
HR (1) | HRP20041231A2 (zh) |
IL (1) | IL165942A (zh) |
IS (1) | IS2487B (zh) |
ME (1) | MEP12408A (zh) |
MX (1) | MXPA05000822A (zh) |
NO (1) | NO20050292L (zh) |
NZ (1) | NZ537615A (zh) |
PL (1) | PL375309A1 (zh) |
RS (1) | RS20050018A (zh) |
TW (1) | TWI274751B (zh) |
UA (1) | UA78805C2 (zh) |
WO (1) | WO2004009585A2 (zh) |
ZA (1) | ZA200500478B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7528124B2 (en) | 2003-08-28 | 2009-05-05 | Taisho Pharmaceutical Co., Ltd. | 1,3-dihydro-2H-indol-2-one derivative |
TW200643015A (en) | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
DE102005015957A1 (de) * | 2005-03-31 | 2006-10-05 | Abbott Gmbh & Co. Kg | Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung |
US8350043B2 (en) | 2005-06-07 | 2013-01-08 | Pharmacopeia, Inc. | Azinone and diazinone V3 inhibitors for depression and stress disorders |
EP2069315B1 (en) | 2006-09-11 | 2011-09-07 | N.V. Organon | Quinazolinone and isoquinolinone acetamide derivatives |
CN103864658B (zh) * | 2014-03-06 | 2016-06-15 | 南京工业大学 | 氮杂环丁酮衍生物及其制备方法与应用 |
CN104447489B (zh) * | 2014-12-29 | 2017-01-11 | 南京工业大学 | 3,4-二芳基马来酰亚胺衍生物及其制备方法与应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2804114B1 (fr) * | 2000-01-25 | 2002-03-08 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
-
2002
- 2002-07-19 FR FR0209242A patent/FR2842527B1/fr not_active Expired - Fee Related
-
2003
- 2003-07-15 AR AR20030102539A patent/AR040571A1/es unknown
- 2003-07-17 DK DK03753652T patent/DK1525198T3/da active
- 2003-07-17 ES ES03753652T patent/ES2254962T3/es not_active Expired - Lifetime
- 2003-07-17 DE DE60302670T patent/DE60302670T2/de not_active Expired - Lifetime
- 2003-07-17 EP EP03753652A patent/EP1525198B1/fr not_active Expired - Lifetime
- 2003-07-17 NZ NZ537615A patent/NZ537615A/en not_active IP Right Cessation
- 2003-07-17 WO PCT/FR2003/002262 patent/WO2004009585A2/fr active IP Right Grant
- 2003-07-17 EA EA200500032A patent/EA008444B1/ru not_active IP Right Cessation
- 2003-07-17 ME MEP-124/08A patent/MEP12408A/xx unknown
- 2003-07-17 RS YUP-2005/0018A patent/RS20050018A/sr unknown
- 2003-07-17 JP JP2004522252A patent/JP4264414B2/ja not_active Expired - Fee Related
- 2003-07-17 AU AU2003271815A patent/AU2003271815B8/en not_active Ceased
- 2003-07-17 CA CA002492224A patent/CA2492224A1/en not_active Abandoned
- 2003-07-17 BR BR0312800-8A patent/BR0312800A/pt not_active IP Right Cessation
- 2003-07-17 AT AT03753652T patent/ATE312092T1/de active
- 2003-07-17 MX MXPA05000822A patent/MXPA05000822A/es active IP Right Grant
- 2003-07-17 UA UAA200500286A patent/UA78805C2/uk unknown
- 2003-07-17 PL PL03375309A patent/PL375309A1/xx not_active IP Right Cessation
- 2003-07-17 CN CNB038218178A patent/CN100425608C/zh not_active Expired - Fee Related
- 2003-07-18 TW TW092119736A patent/TWI274751B/zh not_active IP Right Cessation
-
2004
- 2004-12-22 IL IL165942A patent/IL165942A/en not_active IP Right Cessation
- 2004-12-30 HR HR20041231A patent/HRP20041231A2/hr not_active Application Discontinuation
-
2005
- 2005-01-12 IS IS7641A patent/IS2487B/is unknown
- 2005-01-18 ZA ZA200500478A patent/ZA200500478B/xx unknown
- 2005-01-19 US US11/038,384 patent/US7202267B2/en not_active Expired - Fee Related
- 2005-01-19 NO NO20050292A patent/NO20050292L/no not_active Application Discontinuation
- 2005-09-23 HK HK05108399A patent/HK1074444A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6391076B2 (ja) | アンドロゲン受容体モジュレーターおよびその使用 | |
TWI360541B (en) | Novel compounds | |
JP3992498B2 (ja) | 新規1,3−ジヒドロ−2h−インドール−2−オン誘導体、それらの製造法およびそれらを含む医薬組成物 | |
TWI330636B (en) | Thyroid hormone receptor agonists | |
US6624164B2 (en) | 1,3-dihydro-2H-indol-2-one derivatives, preparation method and pharmaceutical composition containing them | |
TW200808771A (en) | Novel compounds II | |
DE60108633T2 (de) | 1,3-dihydro-2h-indol-2-on derivate und deren verwendung als liganden der arginin-vasopressin v1b und v1a rezeptoren | |
KR20070026357A (ko) | 인돌 유도체, 및 키나제 억제제, 특히 ikk2억제제로서의 그의 용도 | |
FR2896503A1 (fr) | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases | |
EP2265582B1 (fr) | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique. | |
US7202267B2 (en) | Acyloxypyrrolidine derivatives, preparation thereof and application thereof in therapeutic | |
EP2294068B1 (fr) | DERIVES DE 1,3-DIHYDRO-2H-PYRROLO(3,2-b) PYRIDIN-2-ONE, LEUR PREPARATION ET LEURS APPLICATIONS EN THERAPEUTIQUE | |
WO2019096089A1 (zh) | 吲哚嗪衍生物及其在医药上的应用 | |
CN112689630A (zh) | 具有双环核部分的新型lxr调节剂 | |
KR20050019896A (ko) | 아실옥시피롤리딘 유도체, 및 v1b 수용체 또는 v1b 및v1a 수용체 모두의 리간드로서의 그의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |